[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA:A Cancer Journal for Clinicians, 2011, 61(2):69-90. [2] Yang L, Yang G H, Zhou M G, et al. Body mass index and mortality from lung cancer in smokers and nonsmokers:A nationally representative prospective study of 220, 000 men in China[J]. International Journal of Cancer, 2009, 125(9):2136-2143. [3] Bade B C, Dela Cruz C S. Lung cancer 2020:Epidemiology, etiology, and prevention[J]. Clinics in Chest Medicine, 2020, 41(1):1-24. [4] Mao Y S, Yang D, He J, et al. Epidemiology of lung cancer[J]. Surgical Oncology Clinics of North America, 2016, 25(3):439-445. [5] Nasim F, Sabath B F, Eapen G A. Lung cancer[J]. The Medical Clinics of North America, 2019, 103(3):463-473. [6] Rivera G A, Wakelee H. Lung cancer in never smokers[J]. Advances in Experimental Medicine and Biology, 2016, 893:43-57. [7] Romaszko A M, Doboszyńska A. Multiple primary lung canc-er:A literature review[J]. Advances in Clinical and Experimental Medicine, 2018, 27(5):725-730. [8] de Sousa V M L, Carvalho L. Heterogeneity in lung cancer[J]. Pathobiology, 2018, 85(1-2):96-107. [9] Collins L G, Haines C, Perkel R, et al. Lung cancer:Diagnosis and management[J]. American Family Physician, 2007, 75(1):56-63. [10] Schwartz A G, Cote M L. Epidemiology of lung cancer[J]. Advances in Experimental Medicine and Biology, 2016, 893(1):21-41. [11] Fu L, Wang R, Yin L, et al. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer:A meta-analysis[J]. The International Journal of Biological Markers, 2019, 34(3):251-261. [12] Meng X Y, Chen X, Wu W H, et al. Electrochemiluminescent immunoassay for the lung cancer biomarker CYFRA21-1 using MoOx quantum dots[J]. Mikrochimica Acta, 2019, 186(12):855. [13] Janssens E, van Meerbeeck J P, Lamote K. Volatile organic compounds in human matrices as lung cancer biomarkers:A systematic review[J]. Critical Reviews in Oncology/Hematology, 2020, 153:103037. [14] Tsou P H, Lin Z L, Pan Y C, et al. Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer[J]. Cancers (Basel), 2021, 13(6):1431. [15] Coudray N, Ocampo P S, Sakellaropoulos T, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning[J]. Nature Medicine, 2018, 24(10):1559-1567. [16] Guo J X, Wang C D, Xu X Y, et al. DeepLN:An artificial intelligence-based automated system for lung cancer screening[J].Annals of Translational Medicine, 2020, 8(18):1126. [17] Sears C R, Mazzone P J. Biomarkers in lung cancer[J]. Clinics in Chest Medicine, 2020, 41(1):115-127. [18] Seijo L M, Peled N, Ajona D, et al. Biomarkers in lung cancer screening:Achievements, promises, and challenges[J]. Journal of Thoracic Oncology, 2019, 14(3):343-357. [19] Villalobos P, Wistuba I I. Lung cancer biomarkers[J]. Hematology/Oncology Clinics of North America, 2017, 31(1):13-29. [20] Kononov A, Korotetsky B, Jahatspanian I, et al. Online breath analysis using metal oxide semiconductor sensors (electronic nose) for diagnosis of lung cancer[J]. Journal of Breath Research, 2019, 14(1):016004. [21] Ratiu I A, Ligor T, Bocos-Bintintan V, et al. Volatile organic compounds in exhaled breath as fingerprints of lung cancer, asthma and COPD[J]. Journal of Clinical Medicine, 2020, 10(1):32. |